Literature DB >> 21541938

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.

Barbara J Ring1, Jenny Y Chien, Kimberly K Adkison, Hannah M Jones, Malcolm Rowland, Rhys Do Jones, James W T Yates, M Sherry Ku, Christopher R Gibson, Handan He, Ragini Vuppugalla, Punit Marathe, Volker Fischer, Sandeep Dutta, Vikash K Sinha, Thorir Björnsson, Thierry Lavé, Patrick Poulin.   

Abstract

The objective of this study was to evaluate the performance of various allometric and in vitro-in vivo extrapolation (IVIVE) methodologies with and without plasma protein binding corrections for the prediction of human intravenous (i.v.) clearance (CL). The objective was also to evaluate the IVIVE prediction methods with animal data. Methodologies were selected from the literature. Pharmaceutical Research and Manufacturers of America member companies contributed blinded datasets from preclinical and clinical studies for 108 compounds, among which 19 drugs had i.v. clinical pharmacokinetics data and were used in the analysis. In vivo and in vitro preclinical data were used to predict CL by 29 different methods. For many compounds, in vivo data from only two species (generally rat and dog) were available and/or the required in vitro data were missing, which meant some methods could not be properly evaluated. In addition, 66 methods of predicting oral (p.o.) area under the curve (AUCp.o. ) were evaluated for 107 compounds using rational combinations of i.v. CL and bioavailability (F), and direct scaling of observed p.o. CL from preclinical species. Various statistical and outlier techniques were employed to assess the predictability of each method. Across methods, the maximum success rate in predicting human CL for the 19 drugs was 100%, 94%, and 78% of the compounds with predictions falling within 10-fold, threefold, and twofold error, respectively, of the observed CL. In general, in vivo methods performed slightly better than IVIVE methods (at least in terms of measures of correlation and global concordance), with the fu intercept method and two-species-based allometry (rat-dog) being the best performing methods. IVIVE methods using microsomes (incorporating both plasma and microsomal binding) and hepatocytes (not incorporating binding) resulted in 75% and 78%, respectively, of the predictions falling within twofold error. IVIVE methods using other combinations of binding assumptions were much less accurate. The results for prediction of AUCp.o. were consistent with i.v. CL. However, the greatest challenge to successful prediction of human p.o. CL is the estimate of F in human. Overall, the results of this initiative confirmed predictive performance of common methodologies used to predict human CL.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Keywords:  allometry; clearance; computanional ADME; disposition; elimination; first time in human; in vitro-in vivo correlation (IVIVC); pharmacokinetics; protein binding; scaling

Mesh:

Substances:

Year:  2011        PMID: 21541938     DOI: 10.1002/jps.22552

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  37 in total

Review 1.  In vitro platforms for evaluating liver toxicity.

Authors:  Shyam Sundhar Bale; Lawrence Vernetti; Nina Senutovitch; Rohit Jindal; Manjunath Hegde; Albert Gough; William J McCarty; Ahmet Bakan; Abhinav Bhushan; Tong Ying Shun; Inna Golberg; Richard DeBiasio; Berk Osman Usta; D Lansing Taylor; Martin L Yarmush
Journal:  Exp Biol Med (Maywood)       Date:  2014-04-24

2.  Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.

Authors:  Jan H Beumer; Venkateswaran C Pillai; Robert A Parise; Susan M Christner; Brian F Kiesel; Michelle A Rudek; Raman Venkataramanan
Journal:  Br J Clin Pharmacol       Date:  2015-09-19       Impact factor: 4.335

3.  A single-species approach considering additional physiological information for prediction of hepatic clearance of glycoprotein derivate therapeutics.

Authors:  Patrick Poulin
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

4.  Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.

Authors:  Edgar Schuck; Tonika Bohnert; Arijit Chakravarty; Valeriu Damian-Iordache; Christopher Gibson; Cheng-Pang Hsu; Tycho Heimbach; Anu Shilpa Krishnatry; Bianca M Liederer; Jing Lin; Tristan Maurer; Jerome T Mettetal; Daniel R Mudra; Marjoleen Jma Nijsen; Joseph Raybon; Patricia Schroeder; Virna Schuck; Satyendra Suryawanshi; Yaming Su; Patrick Trapa; Alice Tsai; Majid Vakilynejad; Shining Wang; Harvey Wong
Journal:  AAPS J       Date:  2015-01-29       Impact factor: 4.009

Review 5.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

Review 6.  Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.

Authors:  Hannah M Jones; Kapil Mayawala; Patrick Poulin
Journal:  AAPS J       Date:  2012-12-27       Impact factor: 4.009

7.  Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data.

Authors:  Tycho Heimbach; Binfeng Xia; Tsu-han Lin; Handan He
Journal:  AAPS J       Date:  2012-11-10       Impact factor: 4.009

8.  UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria.

Authors:  Christel Brunschwig; Nina Lawrence; Dale Taylor; Efrem Abay; Mathew Njoroge; Gregory S Basarab; Claire Le Manach; Tanya Paquet; Diego Gonzàlez Cabrera; Aloysius T Nchinda; Carmen de Kock; Lubbe Wiesner; Paolo Denti; David Waterson; Benjamin Blasco; Didier Leroy; Michael J Witty; Cristina Donini; James Duffy; Sergio Wittlin; Karen L White; Susan A Charman; Maria Belén Jiménez-Díaz; Iñigo Angulo-Barturen; Esperanza Herreros; Francisco Javier Gamo; Rosemary Rochford; Dalu Mancama; Theresa L Coetzer; Mariëtte E van der Watt; Janette Reader; Lyn-Marie Birkholtz; Kennan C Marsh; Suresh M Solapure; John E Burke; Jacob A McPhail; Manu Vanaerschot; David A Fidock; Paul V Fish; Peter Siegl; Dennis A Smith; Grennady Wirjanata; Rintis Noviyanti; Ric N Price; Jutta Marfurt; Kigbafori D Silue; Leslie J Street; Kelly Chibale
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

9.  Prediction of Drug Clearance from Enzyme and Transporter Kinetics.

Authors:  Priyanka R Kulkarni; Amir S Youssef; Aneesh A Argikar
Journal:  Methods Mol Biol       Date:  2021

10.  Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model.

Authors:  Zhi-wei Gao; Yun-ting Zhu; Ming-ming Yu; Bin Zan; Jia Liu; Yi-fan Zhang; Xiao-yan Chen; Xue-ning Li; Da-fang Zhong
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.